Literature DB >> 6340978

Tumor cell diversity and host responses in cancer metastasis--part II--host immune responses and therapy of metastases.

G L Nicolson, G Poste.   

Abstract

Recent findings that (1) individual tumor cells in a malignant lesion possess widely different metastatic properties and (2) metastases arise from specific subpopulations of metastatic tumor cells have profound implications for eventually understanding and treating metastatic diseases. These findings have also raised serious doubts concerning the appropriateness of many of the experimental approaches currently in use for studying metastasis. Diversity in metastatic phenotype among cells from the same tumor suggests that the usual analyses of tumor cell lines containing multiple heterogeneous subpopulations may not be fruitful. This is especially true for tumors where the metastatic subpopulations represent only an extremely small fraction of the total number of tumor cell subpopulations. In addition, the screening of potential antitumor and antimetastatic agents for their abilities to inhibit the growth of tumors containing widely heterogeneous subpopulations of metastatic and nonmetastatic cells may not be useful in predicting the efficacy of these treatments against metastases. New methodologies must be developed to isolate and characterize the specific cell subpopulations that possess the metastatic phenotype, with the reservation that careful attention must be paid to the stabilities of these malignant cell subpopulations, especially during long-term growth. Understanding the mechanism(s) controlling the rapid generation of phenotypic diversity in tumor subpopulations, and the regulation of subpopulation diversity during progressive growth of primary and metastatic lesions, is of fundamental importance in the design of experimental systems for studying the metastatic process, and eradicating metastases. This review and its companion, as well as our other recent reviews, have dealt with current information on cancer metastasis and where future efforts might be the most promising in discerning this complex process.

Entities:  

Mesh:

Year:  1983        PMID: 6340978     DOI: 10.1016/s0147-0272(83)80005-1

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN: 0147-0272            Impact factor:   3.187


  19 in total

Review 1.  Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy.

Authors:  Megumi Iiizumi; Wen Liu; Sudha K Pai; Eiji Furuta; Kounosuke Watabe
Journal:  Biochim Biophys Acta       Date:  2008-07-22

Review 2.  Implications of tumor progression on clinical oncology.

Authors:  D R Welch; S P Tomasovic
Journal:  Clin Exp Metastasis       Date:  1985 Jul-Sep       Impact factor: 5.150

3.  Tumor progression- and metastasis-associated proteins identified using a model of locally recurrent rat mammary adenocarcinomas.

Authors:  D R Welch; S A McClure; P A Aeed; M J Bahner; L D Adams
Journal:  Clin Exp Metastasis       Date:  1990 Nov-Dec       Impact factor: 5.150

4.  Multiple phenotypic divergence of mammary adenocarcinoma cell clones. I. In vitro and in vivo properties.

Authors:  D R Welch; D B Krizman; G L Nicolson
Journal:  Clin Exp Metastasis       Date:  1984 Oct-Dec       Impact factor: 5.150

5.  Tumor progression, oncogenes and the evolution of metastatic phenotypic diversity.

Authors:  G L Nicolson
Journal:  Clin Exp Metastasis       Date:  1984 Apr-Jun       Impact factor: 5.150

Review 6.  Generation of phenotypic diversity and progression in metastatic tumor cells.

Authors:  G L Nicolson
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

7.  Preventing diversification of malignant tumor cells during therapy.

Authors:  G L Nicolson; R Lotan
Journal:  Clin Exp Metastasis       Date:  1986 Oct-Dec       Impact factor: 5.150

8.  Brain surface invasion and metastasis of murine malignant melanoma variants.

Authors:  G L Nicolson; T Kawaguchi; M Kawaguchi; C Van Pelt
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

9.  Effects of the pyrimido-pyrimidine derivative RX-RA 85 on metastatic tumor cell-vascular endothelial cell interactions.

Authors:  R B Lichtner; G L Nicolson
Journal:  Clin Exp Metastasis       Date:  1987-09       Impact factor: 5.150

10.  Failure of orally administered RA233 to influence B16 melanoma growth or metastasis.

Authors:  C W Stackpole; D M Fornabaio; A L Alterman
Journal:  Clin Exp Metastasis       Date:  1987 Apr-Jun       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.